Streetbeat News

Stock Prices

AAPL

Apple Inc has officially launched the iPhone 15, with strong pre-orders and long lines reported in China, Europe, and the U.S. Wedbush analyst Daniel Ives predicts strong market share gains for Apple, with pre-orders tracking 10% to 12% higher than the iPhone 14. Ives also expects strong sales in India and China, and estimates that iPhone units sold could reach 225 million for fiscal 2024. Apple shares are up 1% to $174.93 on Friday.

Portfolio Pulse from Chris Katje

September 22, 2023 | 3:25 pm

TSLA

Tesla Inc. (NASDAQ:TSLA) has seen an 8% reduction in stock value amid labor controversies and strikes led by the United Auto Workers (UAW) against major automakers. Despite this, Tesla's financial outlook remains resilient, with the stock marking a 114% increase over the year.

Portfolio Pulse from Zaheer Anwari

September 22, 2023 | 3:23 pm

BIDU

A significant bullish stance has been taken on Baidu (NASDAQ:BIDU) by a large investor or institution, as indicated by a large position in Baidu's options. The overall sentiment of these big-money traders is split between 73% bullish and 26% bearish. The whales have been targeting a price range from $134.0 to $150.0 for Baidu over the last 3 months. JP Morgan, Susquehanna, Benchmark, and Loop Capital have given price targets of $200, $175, $210, and $190 respectively.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:15 pm

MMM

3M Company (NYSE:MMM) has agreed to a $9.62 million settlement with the U.S. Treasury Department's Office of Foreign Assets Control (OFAC) over alleged sales to an Iranian entity. This follows a recent settlement with the SEC. The settlement addresses 54 apparent violations of OFAC sanctions on Iran, involving sales of reflective license plate sheeting products to a reseller for a customer in Iran. 3M shares are trading lower by 0.49% at $97.01.

Portfolio Pulse from Shivani Kumaresan

September 22, 2023 | 3:11 pm

ALPMF

ALPMY

MRK

SGEN

Seagen Inc and Astellas Pharma Inc released positive results from the KEYNOTE-A39 Phase 3 EV-302 trial for Padcev combined with Merck & Co Inc's Keytruda versus chemotherapy in bladder cancer. The trial met its dual primary endpoints of overall survival and progression-free survival compared to chemotherapy. The results are expected to confirm the current U.S. accelerated approval of Keytruda in combination with enfortumab vedotin as first-line treatment for urothelial carcinoma. Seagen's shares are up 3.54% at $213.69.

Portfolio Pulse from Vandana Singh

September 22, 2023 | 3:05 pm

FSLR

Over the past 3 months, 23 analysts have published their opinion on First Solar (NASDAQ:FSLR) stock. The company has an average price target of $236.91, an increase of 3.79% from the previous average price target of $228.26. The ratings are derived from company conference calls, financial statements, and insider conversations.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:01 pm

MIDD

Five analysts have given bullish ratings for Middleby (NASDAQ:MIDD) in the last quarter, with an average 12-month price target of $167.0, a decrease of 1.18% from the previous average price target of $169.00.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:01 pm

AXP

American Express (NYSE:AXP) has outperformed the market over the past 15 years, producing an average annual return of 10.9%. If an investor had bought $100 of AXP stock 15 years ago, it would be worth $389.14 today. The company currently has a market capitalization of $113.20 billion.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:00 pm

JAMF

Over the past 3 months, 8 analysts have published their opinion on Jamf Holding (NASDAQ:JAMF) stock. The average price target for the stock is $29.38, with a high of $35.00 and a low of $22.00. This average price target has increased by 24.12% over the past month.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:00 pm

TRV

Travelers Companies (NYSE:TRV) has outperformed the market over the past 15 years, producing an average annual return of 10.83%. If an investor had bought $1000 of TRV stock 15 years ago, it would be worth $3,826.14 today.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:00 pm